However, considering the prevalence and adverse outcome of ASXL1 mutations in AML, it is essential to identify the molecular landscape of ASXL1+ AML patients for establishing precise risk stratification in this subgroup of AML. The gene discussed is ASXL1; the disease is acute myeloid leukemia.